MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data.Laurence Albigès, Sabina Signoretti, Anders Mellemgaard et al.|Journal of Clinical Oncology|2020Cited by 4
Abstract CT022: First data disclosure of the Phase I trial of the first in class combination of WEE1 inhibitor zedoresertib with PKMYT1 inhibitor lunresertib in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A genomic alterationsTimothy A. Yap, Alison M. Schram, Rahul Aggarwal et al.|Cancer Research|2026Cited by 0